XPG rs2296147 T>C polymorphism predicted clinical outcome in colorectal cancer
Metrics: PDF 691 views | HTML 840 views | ?
Fang Wang1,*, Shao-Dan Zhang1,*, Hong-Mei Xu3,*, Jin-Hong Zhu4, Rui-Xi Hua5, Wen-Qiong Xue1, Xi-Zhao Li1, Tong-Min Wang1, Jing He1,2, Wei-Hua Jia1
1Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Department of Experimental Research, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, Guangdong, China
2Department of Pediatric Surgery, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangzhou 510623, Guangdong, China
3Reproductive Medical Center, Department of Obstetrics and Gynecology, Sun Yat-Sen Memorial Hospital, Guangzhou 510120, Guangdong, China
4Molecular Epidemiology Laboratory and Department of Laboratory Medicine, Harbin Medical University Cancer Hospital, Harbin 150081, Heilongjiang, China
5Department of Oncology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, Guangdong, China
*These authors contributed equally to this work
Jing He, e-mail: email@example.com
Wei-Hua Jia, e-mail: firstname.lastname@example.org
Keywords: colorectal cancer, xeroderma pigmentosum group G, single nucleotide polymorphism, progression-free survival, overall survival
Received: September 22, 2015 Accepted: January 23, 2016 Published: February 12, 2016
Xeroderma pigmentosum group G (XPG), one of key components of nucleotide excision repair pathway (NER), is involved in excision repair of UV-induced DNA damage. Single nucleotide polymorphisms (SNPs) in the XPG gene have been reported to associate with the clinical outcome of various cancer patients. We aimed to assess the impact of four potentially functional SNPs (rs2094258 C>T, rs2296147 T>C, rs751402 G>A, and rs873601 G>A) in the XPG gene on prognosis in colorectal cancer (CRC) patients. A total of 1901 patients diagnosed with pathologically confirmed CRC were genotyped for four XPG polymorphisms. Cox proportional hazards model analysis controlled for several confounding factors was conducted to compute hazard ratios (HRs) and 95% confidence intervals (CIs). Of the four included SNPs, only rs2296147 was shown to significantly affect progression-free survival (PFS) in CRC. Patients carrying rs2296147 CT/TT genotype had a significantly shorter median 10 years PFS than those carrying CC genotype (88.5 months vs. 118.1 months), and an increased progression risk were observed with rs2296147 (HR = 1.324, 95% CI = 1.046–1.667). Moreover, none of the four SNPs were associated with overall survival. In conclusion, our study showed that XPG rs2296147 CT/TT variants conferred significant survival disadvantage in CRC patients in term of PFS. XPG rs2296147 polymorphism could be predictive of unfavorable prognosis of CRC patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.